While it is certainly important to keep all these concerns in mind, we believe the demonstrated benefits of myostatin blockade both in preclinical models of DMD and even in DMD patients receiving a non-selective myostatin inhibitor [29] outweigh the potential risks of further testing this more selective myostatin antibody. Here, MSTN is linked to Duchenne muscular dystrophy.